A 2-year-old fledgling biotech steers into PhIII and nabs a quick $565M buyout deal
A biotech startup in Europe with a very careful focus on a single Phase III therapy has quickly parlayed a drug/device play for a rare lung disease into a $565 million buyout deal.
The Italian pharma Zambon is paying close to $160 million in cash to get its hands on Breath Therapeutics, which officially launched just a couple of years ago with a $46 million A round and technology spun out of PARI Pharmaceuticals and the lab of Aldo Iacono at the University of Maryland.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
